Leerink Partners Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 94.3%

Neg 94.3% Neu 0% Pos 0%

Leerink Partners analyst Jeffrey La Rosa maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target from $9 to $7.